Inovio Pharmaceuticals, Inc. (INO) Presents at The Citizens Life Sciences Conference 2026 Transcript

Company Overview - Inovio is a clinical stage biotech company focused on developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases [3]. Product Development - The company has submitted a Biologics License Application (BLA) for its lead program, INO-3107, which targets recurrent respiratory papillomatosis (RRP) caused by HPV types 6 and 11 [4]. - The BLA has been accepted for review by the FDA under the accelerated approval program, with a PDUFA target date set for October 30 of this year [4]. - Inovio holds orphan drug and breakthrough therapy designations, as well as orphan drug designation in the EU for INO-3107 [4]. Regulatory Strategy - Inovio has requested a meeting with the FDA to discuss preliminary comments received regarding eligibility for the accelerated approval pathway and does not plan to seek approval under the traditional pathway [5].